secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001104659-23-091494
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRX Pharmaceuticals enters $2M at-the-market equity offering with H.C. Wainwright
--------------------------------------------------------------------------------

- At-the-market offering of up to $2,000,000 of common stock; sales at market prices via Nasdaq.
- H.C. Wainwright will receive 3.0% commission on gross proceeds plus expense reimbursement.
- Sales are made under an effective shelf registration statement (S-3) filed June 2022.
- Company is not obligated to sell any shares; agreement terminates upon full sale or earlier termination.
- Customary reps, warranties, indemnification, and conditions apply to the agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000110465923091494/0001104659-23-091494-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000110465923091494/tm2323641d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-091494

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer